News

Financing High-Risk Medical Research

A Proposal from FasterCures by Melissa Stevens (Milken Institute Review) - In the past few years, the media has showered us with headlines about recordsetting biotech financing – outsized venture-capital rounds, unprecedented public market appetite for IPOs, and robust sector returns. But a closer look suggests there is more froth than substance at this frontier of medicine and science.

Read More

Could 2015 Be a Turning Point in NIH Funding?

For the National Institutes of Health and its supporters, 2015 could turn out to be a pretty good year. As Congress continues negotiations on a mammoth omnibus spending package, advocates are hopeful that their favored institution is becoming a congressional priority again—and that an extended period of uncertainty may be coming to a close.

Read More

Cell scientist to watch – Christine Mayr

Abstract: Before completing a PhD in immunology at the Humbolt University of Berlin, Christine Mayr received a medical degree from the Freie Universität Berlin. She received postdoctoral training with Michael Hallek at the Ludwig Maximillian University in Munich.

Read More

If Cancer Becomes Biden’s Cause, a Bold but Polarizing Doctor Is On Call

WASHINGTON — One day last winter, desperate as his son fought for his life against a killer brain cancer, Vice President Joseph R. Biden Jr. and his family reached out to one of America’s most famous, and controversial, doctors for help.

Read More

Tumor Exosome Protein Signatures Predict Future Organ Sites of Cancer Spread

Findings By Weill Cornell Medicine Explain Paget’s “Seed and Soil” Theory of Metastasis

Read More

Why Are More Science Funders Investing in Young Researchers? Here’s Part of the Story

We report frequently enough about research grants and prizes specifically for young investigators—particularly in the biomedical sciences—that some readers have asked why so many foundations make it a point to earmark this early-career funding. What's the obsession with youth? We gray-hairs want to know.

Read More

Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis

Abstract: Cohesin complex members have recently been identified as putative tumor suppressors in hematologic and epithelial malignancies. The cohesin complex guides chromosome segregation; however, cohesin mutant leukemias do not show genomic instability.

Read More

Loss of BAP1 function leads to EZH2-dependent transformation

Abstract: The tumor suppressors BAP1 and ASXL1 interact to form a polycomb deubiquitinase complex that removes monoubiquitin from histone H2A lysine 119 (H2AK119Ub).

Read More

The Pershing Square Sohn Cancer Research Alliance Now Accepting Applications for the 2016 Prize for Young Investigators in Cancer Research

NEW YORK, Oct. 1, 2015 /PRNewswire-USNewswire/ — The Pershing Square Sohn Cancer Research Alliance (PSSCRA) today announced the opening of applications for its Prize for Young Investigators in Cancer Research.

Read More

The case of philanthropy: bringing scientists and philanthropic donors together, for good

By Olivia Tournay Flatto (Disease Models & Mechanisms) – Summary: Philanthropists and scientists share many common interests, and yet they are not familiar with each other’s ways of thinking. This Editorial highlights how to improve their mutual understanding to advance research and life sciences.

Read More